Advertisement
Dr. Diaz-Buxo is Chief Medical Officer and Senior Vice President, RenalTherapies Group, Fresenius Medical Care North America. He is also SeniorAdvisor for Global Home Therapies, Fresenius Medical Care. He is known for hisdevelopment of continuous cyclic peritoneal dialysis and various PD cyclers,his development of external occlusion for PD disconnect systems, and earlyidentification of acute renal failure from contrast material injection. Dr.Diaz-Buxo has been a physician at the Mayo Clinic, the Carolinas MedicalCenter, the University of North Carolina, Chapel Hill, and has served onmultiple editorial and review boards, including Clinical Nephrology,Peritoneal Dialysis International, Kidney International, and American Journalof Kidney Diseases. He has published more than 270 peer-reviewed papers,editorials and book chapters. He has received awards from the American KidneyFund, the National Kidney Foundation and been listed in the Best Doctors inAmerica and Who's Who in Medicine.
Advertisement
Dr. Ing has previously worked as a staff physician in the Department ofMedicine at the Veterans Affairs Hospital in Hines, IL. He has provided renalcare to veterans for more than 25 years and has organized educational seminarsfor patients and healthcare professionals alike. He has been on the editorialboards for the International Journal of Artificial Organs, Artificial Organs,Transactions of the American Society for Artificial Internal Organs, Kidney,Journal of American Paraplegia Society, Hemodialysis International andPeritoneal Dialysis International. Dr. Ing has authored more than 250publications in the area of dialysis with emphasis on isolated ultrafiltration,complications of dialysis, dialysate composition and peritoneal dialysis. Heis also co-editor of the Handbook of Dialysis which is widely used around theworld. He was presented the National Torchbearer Award by the American KidneyFund in 2005. The American Association of Kidney Patients (AAKP) recentlypresented the Medal of Excellence Award to Dr. Ing.
"We are delighted to have Dr. Diaz-Buxo and Dr. Ing join our MedicalAdvisory Board," said Peter DeComo, President and CEO of Renal Solutions."The addition of these distinguished, renal experts to our advisory board ofwell known and highly experienced physicians further demonstrates RenalSolutions' and Fresenius' commitment to advancing sorbent therapy for improvedrenal care."
RSI is the leader in advancing sorbent technology for renal replacementtherapy in acute or chronic dialysis settings. The company was acquired byFresenius Medical Care in November of 2007.
About Renal Solutions, Inc
Renal Solutions, a wholly-owned subsidiary of Fresenius Medical Care, isleading the advancement of sorbent technology for improved renal replacementtherapy. Renal Solutions' patented, innovative sorbent cartridges requireonly 6 liters of potable tap water, the lowest volume option available, toprovide highly pure dialysate for up to 8 hours of therapy. SMARRT (SorbentManagement for Advanced Renal Replacement Therapy) provides freedom fromcomplex water treatment systems, opening new treatment options across chronicand acute dialysis settings. Backed by over 6 million safe and effectiveclinical treatments, SMARRT is a proven technology that will ultimately driverenal replacement therapy toward true portability and future wearabletechnology.
For more information about Renal Solutions visit the Company's website atwww.renalsolutionsinc.com.
This press release contains forward-looking statements, which if not basedon historical facts, involve risks and uncertainties. Our actual results maydiffer materially from th
